Recent studies on the neurocognitive effects of second-generation antipsychotic medications

Current Opinion in Psychiatry

Volumn 15, Issue 1, 2002, Pages 25-29

  Green, Michael F ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT;

ATTENTION; COGNITION; DRUG EFFECT; HUMAN; MEMORY; PERCEPTION; REVIEW; SCHIZOPHRENIA;

EID: 0036143756     PISSN: 09517367     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001504-200201000-00005     Document Type: Review

References (28)

1. Neurocognitive functioning in patients with schizophrenia
2. What are the functional consequences of neurocognitive deficits in schizophrenia?
3. Neurocognitive deficits and functional outcome in schizophrenia: Are we measuring the 'right stuff'?
4. Cognitive effects of typical antipsychotic treatment: Another look
5. Neuroleptics: Effects on neuropsychological function in chronic schizophrenic patients
6. Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine
7. The effects of clozapine on symptom reduction, neurocognitive function, and clinical management in treatment refractory state hospital schizophrenic inpatients
8. Neuropsychological change in schizophrenia after 6 weeks of clozapine
9. The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: A review and meta-analysis
10. The effect of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia
11. Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, and haloperidol
12. Changes in cognitive functioning with risperidone and olanzapine treatment: A large-scale double blind randomized study
13. Effects of olanzapine and other antipsychotics on cognitive function in chronic schizophrenia: A longitudinal study
14. Neurobiological studies of sensory gating in schizophrenia
15. Normalization of information processing deficits in schizophrenia with clozapine
16. Normal P50 suppression in schizophrenia patients treated with atypical antipsychotic medication
17. Effects of neuroleptic medications on speech disorganization in schizophrenia: Biasing associative networks towards meaning
18. Improvement in cognition associated with novel antipsychotic drugs: A direct drug effect or reduction in EPS?
19. Differences in frontal cortical activation by a working memory task after substitution of risperidone for typical antipsychotic drugs in patients with schizophrenia
20. Comparison of the effects of risperidone and haloperidol on regional cerebral blood flow in schizophrenia
21. Studies of the cognitive change in patients with schizophrenia following novel antipsychotic treatment
22. Atypical antipsychotics in the treatment of schizophrenia: Systematic overview and meta-regression analysis
23. The neurocognitive effects of low-dose haloperidol: A two-year comparison with risperidone
24. Neurocognitive deficit in schizophrenia: A quantitative review of the evidence
25. Translating the basic and clinical cognitive neuroscience of schizophrenia to drug development and clinical trials of antipsychotic medications
26. Assessing the validity of an animal model of deficient sensorimotor gating in schizophrenic patients
27. Reversal of antipsychotic-induced working memory deficits by short-terms dopamine D1 receptor stimulation